Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer questions focused on the optimizing BTK inhibitor therapy for previously untreated patients with CLL considering presentation characteristics and drug pharmacology.Content based on an online CME program supported by an educational grant from AstraZeneca.
Link to full program, including associated downloadable slidesets: https://www.clinicaloptions.com/oncology/programs/cll-horizons
Expert case-based text module on managing toxicities with BCL-2 and PI3K inhibitors in CLL, from Clinical Care Options (CCO)
Experts review key data for multiple myeloma at the 2021 hematology annual meeting, from Clinical Care Options (CCO)
Clinical Care Options (CCO): Expert review of key data in MDS and MPN from the 2021 ASH annual meeting
Clinical Care Options (CCO): Experts John M. Burke, MD, and Peter Martin, MD, review key data in lymphomas and CLL presented at the 2021 American Society of Hematology Annual Meeting